Skip to search formSkip to main contentSkip to account menu

baricitinib

Known as: 3-Azetidineacetonitrile, 1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)- 
An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities… 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (2)

AzetidinesSulfonamides

Narrower (2)

INCB028050LY3009104
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
THU0078 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS
Background: Baricitinib (bari), is an oral, selective inhibitor of Janus kinase (JAK) 1/JAK 2, to treat moderately to severely… 
Review
2019
Review
2019
JAK-STAT inhibitors for the treatment of immunomediated diseases
2019
2019
FRI0164 INCIDENCE RATE AND CHARACTERIZATION OF HERPES ZOSTER IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: AN UPDATE FROM BARICITINIB CLINICAL STUDIES
Background Baricitinib (BARI) is a selective inhibitor of Janus kinase (JAK) 1 and JAK2, approved for the treatment of moderately… 
2018
2018
Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials
Abstract Objectives: To evaluate efficacy/safety of baricitinib for rheumatoid arthritis (RA) in Japanese subpopulations from… 
2018
2018
SAT0218 Efficacy and safety of baricitinib in mtx-ir patients with rheumatoid arthritis: 52 week results from a phase 3 study (RA-BALANCE)
Background: Baricitinib (BARI) is an oral selective inhibitor of Janus kinase 1 (JAK1) and JAK2. In the EU and some other… 
2018
2018
Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying…
Background Baricitinib was efficacious in a 24-week phase III study in patients with rheumatoid arthritis (RA) and an inadequate… 
2017
2017
Tracking JAKs in spondyloarthritis: rationale and expectations
In this issue, Van der Heijde and colleagues1 report the results of a randomised, prospective, placebo-controlled, dose-ranging… 
2016
2016
OP0228 Baricitinib Dose Step-Down Following Disease Control in Patients with Rheumatoid Arthritis
Background Ph3 studies demonstrated clinical efficacy of 2 different once-daily (QD) doses of baricitinib (bari) (2mg and 4mg) in… 
2015
2015
Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
Review
2013
Review
2013
Small molecular compounds in development for rheumatoid arthritis.
PURPOSE OF REVIEW: To provide an update on the development of small molecular compounds as novel therapeutics for the treatment… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)